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DEBATE
Triple artemisinin-containing combination 
anti-malarial treatments should be 




Managing multidrug resistant malaria can be problematic if currently available artemisinin-containing anti-malarial 
combination treatments are not used appropriately. Here, I debate that the best way to manage multidrug resistant 
malaria is to make best use of existing treatments and to develop new classes of anti-malarial drugs and not to make 
‘triple combination therapies’ when there is already resistance to one or more proposed components.
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Almost 3  years after suggesting that declining efficacies 
of ACT may benefit from ‘inclusive debates’ it is gratify-
ing to implement this suggestion [1]. I am grateful for the 
invitation to present the case against triple artemisinin-
containing combination anti-malarial treatments. 
This case rests on the same principles that are used to 
shut down any flawed drug development programme 
where ‘go no-go’ decisions bear in mind the following 
considerations:
Primum non nocere—‘at least do no harm’ in the con-
text of triple ACT suggests in the first instance that the 
risk of any toxicities from combinations should be kept 
to a minimum. Adding anti-malarial combinations to 
each other will inescapably increase the risks of adverse 
events, such as hepatic toxicity, cardiotoxicity and other 
toxicities in ways that may not be predictable from the 
profiles of existing combinations. At best, such risks will 
be additive when combined. In addition to toxicity, there 
is also an increased likelihood that triple combinations 
will be less well tolerated by patients, so that even if theo-
retical advantages of improved efficacy were to be shown, 
a less well tolerated triple combination course may not be 
taken to completion as often as the conventional ACT.
Affordability—triple combinations will be more expen-
sive than conventional ACT. They will have to be for-
mulated differently, costs of assessing their safety and 
efficacy will have to be included in final product costings 
and regulatory approvals will also demand resources.
Even to consider triple combinations, there would have 
to be clear evidence that we are running out of conven-
tional combinations. We can do much more with exist-
ing and still effective conventional ACT rather than 
spending scarce resources on developing new triples 
[2, 3]. Despite clamour to the contrary, according to the 
World Health Organization we are not yet running out 
of effective artemisinin-based combinations. In address-
ing the issue of ‘artemisinin resistance’ Dr. Pedro Alonso 
made it clear that some combinations are still effective in 
the Greater Mekong Subregion (GMS) where resistance 
to other artemisinin-based combinations has arisen [4]. 
It is unsurprising that the funders of studies on ACT in 
GMS may take a contrary position on the whole concept 
of artemisinin resistance. Ensuing exchanges between 
the WHO and the Wellcome Trust left some observers 
confused whilst providing reassurance that we still have 
effective treatments for malaria, even in GMS [5].
But what about the risk that even those artemisinin-
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And the argument that there is urgency now to develop 
triples so that we are ready for that eventuality? To con-
sider this argument fully, we should first look at the con-
cept of ‘artemisinin resistance’, which has been developed 
and used by researchers, especially in GMS, to advance 
their arguments for funding and trials, including no 
doubt to test triple combinations. ‘Artemisinin resistance’ 
is defined by the phenotype of delayed parasite clearance 
when treatment is given with monotherapy (in research 
studies) or in combination. There are many flaws with this 
definition, probably one of the most important being that 
this delayed parasite clearance phenotype is not predic-
tive of treatment failure with a particular ACT [3, 6]. We 
know that if say mefloquine/artesunate fails in a particu-
lar geographic region, this is associated with increased 
copy numbers of pfmdr1 in parasites that have become 
resistant to the mefloquine component of this combina-
tion. These parasites can also display the delayed parasite 
clearance phenotype. Parasites with these characteristics 
nevertheless can remain sensitive to DHA/piperaquine 
treatments despite being labelled ‘artemisinin resist-
ant’. How can they be classified as artemisinin resistant 
if the common effective component of ACT is an arte-
misinin [2]? We, and others [7, 8], made this argument 
several years ago and were accused of aiding the spread 
of artemisinin resistance. We defended ourselves at the 
time and subsequent clinical and molecular studies are 
consistent with our suggestions. Understanding of part-
ner drug resistance mechanisms (for example, to pipe-
raquine) has advanced in the intervening years, and the 
limitations of monitoring for kelch13 mutations parasites 
with delayed clearances have also become clearer. Thus, 
kelch13 mutations associated with delayed parasite clear-
ance are not predictive of treatment failures with ACT, 
consistent with the lack of such predictive value of the 
phenotype itself [9].
Neither are those working in GMS arguing for the 
return of quinine to treat severe malaria in ‘artemisinin 
resistant’ parasites. The most severely affected patients 
should be given the most effective drugs to minimise 
mortality. If ‘artemisinin resistance’ were clinically signif-
icant then surely artesunate should no longer be consid-
ered the drug of first choice in the region?
So where does that leave usage of ACT? Much more 
investment and effort should be put into implementation 
studies for using existing artemisinin-based combina-
tions. After all, it is national malaria control programmes 
that are responsible for delivering effective therapies. 
These should be supported by the best available evidence, 
rapidly obtained, to choose the most effective ACT for a 
region [3]. Included in this argument is the importance 
of using drugs that are verified in terms of their composi-
tion, so that substandard supplies are not used and then 
incorrectly claimed to have failed in particular regions 
[10].
The most effective ACT can be assessed with results 
from molecular and clinical studies using validated 
markers for resistance (without reliance on the delayed 
parasite clearance phenotype). More investment in deliv-
ering currently effective artemisinin-based combinations, 
and conversely in discontinuing ineffective combina-
tions (until they regain effectiveness) will yield immedi-
ate improvements in treatment outcomes, and that in a 
highly cost-effective manner.
If ACT continues to fail in conventional treatment 
doses, then there is always the option of extending 
treatment regimens beyond 3  days. This would restore 
efficacy without adding disproportionately to costs, 
although monitoring for additional toxicities would still 
be required [11]. This approach is immediately available 
and, therefore, the least expensive one compared with 
developing new drugs or triple combinations.
If triple combinations continue to reassert themselves 
on drug development agendas, then what principles 
should guide their development? These principles were 
summarized decades ago by White and Olliaro, and a 
couple of points are worth revisiting. Writing about sulf-
adoxine/pyrimethamine (S/P) combined with mefloquine 
[12]:
“This fixed dose combination has never been used 
extensively, and the benefit of the triple combina-
tion over single-drug regimens has never been estab-
lished. …. the combination failed to prevent resist-
ance developing in Thailand where it was deployed 
from 1984. There were two reasons: (1) P. falciparum 
was already highly resistant to S/P; and (2) the phar-
macokinetics of the drugs were not well matched.”
Experience with S/P + mefloquine highlights well 
another key consideration for developing any triple com-
bination, namely that if there is already resistance to one 
or more components of the combination then there are 
unlikely to be any lasting benefits from developing triple 
combinations with them. Most artemisinin partner drugs 
with reasonably matched elimination half-lives have 
already selected for resistance in populations where there 
are treatment failures with ACT (TFACT). After all, there 
would not be any need to develop triples if conventional 
ACT was effective, and if an artemisinin-based combi-
nation is not active, it should not be included in triples. 
It would seem to make more sense to use conventional 
ACT nimbly and responsively in conventional combina-
tions after establishing efficacies.
In the next few years, entirely new classes of anti-
malarial will become available through efforts of organi-
zations such as MMV and its collaborators. The greatest 
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priority will be to ensure the best partner drugs for these 
new classes so that new combination therapies become 
available. There will undoubtedly be an opportunity cost 
to the development of new combinations if resources are 
expended on developing the higher risk triple combina-
tion approaches with existing anti-malarials.
We have been hearing for many years about the catas-
trophe of anti-malarial resistance in GMS, and how 
resources are needed to contain this phenomenon that 
puts at risk our global anti-malarial strategy. However, 
there are only a few hundreds of deaths in GMS from 
malaria each year, compared with those in sub-Saharan 
African countries with much higher endemicities [13]. 
The real failures in controlling malaria stem from escape 
from vector control, inadequate implementation in some 
national control programmes and lack of nimbleness in 
changing treatment regimens in the face of TFACT.
We should stop calling delayed parasite clearance ‘arte-
misinin resistance’, focus on using existing combinations 
most effectively and support the development of new 
classes of anti-malarials. And we should drop the poten-
tially toxic, ineffective and expensive idea of triple combi-
nations along the way.
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